The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer.
A. Tsuburaya
No relevant relationships to disclose
K. Yoshida
No relevant relationships to disclose
M. Kobayashi
No relevant relationships to disclose
S. Yoshino
No relevant relationships to disclose
Y. Miyashita
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose
K. Oba
No relevant relationships to disclose
M. E. Buyse
No relevant relationships to disclose
J. S. Macdonald
No relevant relationships to disclose
J. Sakamoto
No relevant relationships to disclose